Simon GR - Search Results

1

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Simon GR, et al. Cancer. 2008 May 1;112(9):2021-9. doi: 10.1002/cncr.23360. Cancer. 2008. PMID: 18300255 Free article. Clinical Trial.

2

Small-cell lung cancer.

Simon G, Ginsberg RJ, Ruckdeschel JC. Simon G, et al. Chest Surg Clin N Am. 2001 Feb;11(1):165-88, ix. Chest Surg Clin N Am. 2001. PMID: 11253596 Review.

3

Small cell lung cancer.

Simon GR, Wagner H; American College of Chest Physicians. Simon GR, et al. Chest. 2003 Jan;123(1 Suppl):259S-271S. doi: 10.1378/chest.123.1_suppl.259s. Chest. 2003. PMID: 12527584 Review.

4

Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.

Simon GR, Bunn PA Jr. Simon GR, et al. Cancer Invest. 2003;21(1):87-104. doi: 10.1081/cnv-120005919. Cancer Invest. 2003. PMID: 12643013 Review.

5

Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.

Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Simon GR, et al. Cancer Control. 2003 Sep-Oct;10(5):388-95. doi: 10.1177/107327480301000506. Cancer Control. 2003. PMID: 14581894 Free article. Clinical Trial.

6

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer.

Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. Bepler G, et al. J Clin Oncol. 2004 May 15;22(10):1878-85. doi: 10.1200/JCO.2004.12.002. J Clin Oncol. 2004. PMID: 15143080

7

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung.

Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Nordquist LT, et al. Among authors: simon gr. Chest. 2004 Aug;126(2):347-51. doi: 10.1378/chest.126.2.347. Chest. 2004. PMID: 15302716

8

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.

Simon GR, Sharma S, Cantor A, Smith P, Bepler G. Simon GR, et al. Chest. 2005 Mar;127(3):978-83. doi: 10.1378/chest.127.3.978. Chest. 2005. PMID: 15764785

9

Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.

Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Chiappori A, et al. Oncology. 2005;68(4-6):382-90. doi: 10.1159/000086979. Epub 2005 Jul 12. Oncology. 2005. PMID: 16020967 Review.

10

Adjuvant chemotherapy for non-small cell lung cancer.

Crane EJ, Simon G. Crane EJ, et al. Curr Treat Options Oncol. 2006 Jan;7(1):51-8. doi: 10.1007/s11864-006-0031-8. Curr Treat Options Oncol. 2006. PMID: 16343368 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters